BCRX
HealthcareBioCryst Pharmaceuticals, Inc. · Biotechnology · $2B
What is BioCryst Pharmaceuticals, Inc.?
BioCryst Pharmaceuticals is a small-cap biotechnology company focused on discovering oral, small-molecule medicines for rare and serious diseases. Headquartered in Durham, North Carolina, the company has built a commercial presence around hereditary angioedema treatment while advancing a pipeline of novel therapies.
BioCryst generates revenue primarily through ORLADEYO, an oral treatment for hereditary angioedema — a rare, potentially life-threatening condition. The company also markets peramivir-based influenza therapies in partnership with regional pharmaceutical companies across multiple geographies. Beyond its commercial products, BioCryst is advancing a clinical pipeline targeting complement-mediated diseases, fibrodysplasia ossificans progressiva, and dangerous RNA viruses, funded in part through government and institutional collaborations.
BioCryst was founded in 1986 and is headquartered in Durham, North Carolina.
- ORLADEYO — oral hereditary angioedema therapy
- RAPIVAB / RAPIACTA / PERAMIFLU — intravenous influenza treatments
- BCX9930 — oral factor D inhibitor in Phase II trials
- BCX9250 — oral ALK-2 inhibitor for fibrodysplasia ossificans progressiva
- Galidesivir — antiviral candidate targeting Ebola, Marburg, and Zika
Is BCRX a Good Stock to Buy?
UQS Score rates BCRX as Good overall, reflecting a balanced profile across its five analytical pillars.
The Quality pillar stands out as the strongest signal for BioCryst, suggesting the company's underlying business fundamentals compare favorably within its peer group. The Risk and Valuation pillars also register positively, indicating that the stock does not carry the elevated risk profile or stretched pricing often associated with clinical-stage biotechs.
The Moat and Growth pillars both sit at Neutral, pointing to limited competitive entrenchment and a growth trajectory that has yet to clearly differentiate BioCryst from the broader small-cap biotech landscape.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BCRX pay dividends?
No — BioCryst Pharmaceuticals, Inc. does not currently pay a dividend.
BioCryst does not currently pay a dividend. This is typical for clinical-stage and early-commercial biotechnology companies, which generally reinvest available capital into research, pipeline development, and commercialization efforts. Investors in BCRX are primarily seeking potential value creation through drug approvals and revenue growth rather than income distributions.
When does BCRX report earnings?
BioCryst Pharmaceuticals reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Each quarterly report gives investors an opportunity to track ORLADEYO's commercial uptake, pipeline milestones, and cash runway — all key indicators for a company at BioCryst's stage. Revenue trends and operating expense management tend to be the focal points for the market each reporting cycle.
For the most recent quarter's results and guidance, visit BioCryst Pharmaceuticals' investor relations page directly.
BCRX Price History
-45.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in BioCryst Pharmaceuticals, Inc.?
Based on BioCryst Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BCRX Long-term Outlook
BioCryst's fundamental outlook is shaped by the commercial trajectory of ORLADEYO in the hereditary angioedema market and the progress of its clinical pipeline. The Neutral Growth pillar suggests the company's near-term expansion path is not yet clearly established, while the Good Risk rating indicates the business is managing its operational and financial risks at a level above many small-cap biotech peers. A positive Valuation pillar label suggests the market has not yet priced in an overly optimistic scenario, which may leave room for upside if pipeline catalysts materialize.
Growth drivers
- Continued ORLADEYO patient uptake in hereditary angioedema
- Potential pipeline readouts from BCX9930 and BCX9250 clinical trials
- Government and institutional partnerships supporting antiviral research
Key risks
- Clinical trial failures or delays across the development pipeline
- Competitive pressure in the hereditary angioedema treatment space
- Cash management and funding requirements for ongoing trials
BCRX vs Peers
BioCryst operates in a competitive small-cap biotech space alongside several companies pursuing rare-disease and specialty therapeutic programs.
Sionna focuses on cystic fibrosis, targeting a different rare-disease niche than BioCryst's angioedema and antiviral programs.
Trevi is developing treatments for chronic pruritus and respiratory conditions, giving it a distinct therapeutic focus from BioCryst's oral small-molecule platform.
Mineralys targets cardiorenal diseases with its aldosterone-focused pipeline, differentiating it from BioCryst's rare-disease and antiviral strategy.
Frequently Asked Questions
What does BioCryst Pharmaceuticals do?
BioCryst Pharmaceuticals discovers and commercializes oral, small-molecule medicines for rare and serious diseases. Its lead commercial product, ORLADEYO, treats hereditary angioedema. The company also markets influenza therapies and is advancing a clinical pipeline targeting complement-mediated diseases, a rare bone disorder, and dangerous RNA viruses.
Does BCRX pay dividends?
BioCryst does not pay a dividend. Like most clinical-stage and early-commercial biotechs, the company reinvests its capital into research, pipeline advancement, and commercialization rather than returning cash to shareholders through distributions.
When does BCRX report earnings?
BioCryst reports earnings on a quarterly basis, in line with standard US-listed company practice. For the exact schedule and most recent results, check the investor relations section of BioCryst's official website.
Is BCRX a good stock to buy?
UQS Score rates BCRX as Good overall. The Quality pillar is the standout strength, while Risk and Valuation also register positively. Moat and Growth are both Neutral, reflecting a company still building its competitive position. The complete pillar breakdown is available to UQS Pro members.
Is BCRX overvalued?
The UQS Valuation pillar for BCRX is rated Good, suggesting the stock is not trading at a stretched premium relative to its fundamentals. That said, valuation in biotech can shift quickly with clinical trial outcomes. View the full valuation analysis on UQS Pro.
How does BCRX compare to its competitors?
BioCryst competes in the small-cap rare-disease biotech space alongside companies like Sionna Therapeutics, Trevi Therapeutics, and Mineralys Therapeutics. Each pursues different therapeutic areas. BioCryst's differentiation lies in its commercial ORLADEYO franchise and its oral small-molecule drug discovery platform.
What is BCRX's market cap bracket?
BioCryst Pharmaceuticals is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and growth potential compared to large- or mega-cap peers, but also greater sensitivity to clinical and commercial execution risks.
Who founded BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals was founded in 1986. Detailed founding history, including founder information, is widely available through the company's official corporate history and public filings.
Is BCRX a long-term quality investment?
From a long-term quality perspective, BCRX's Good UQS Score — anchored by a Strong Quality pillar and positive Risk and Valuation ratings — provides a constructive starting point. However, the Neutral Moat and Growth pillars suggest the company's long-term competitive durability is still developing. Pro members can access the full multi-pillar view.
What is the main competitive advantage of BioCryst Pharmaceuticals?
BioCryst's core strength lies in its oral small-molecule drug discovery platform, which has produced a commercially approved rare-disease therapy in ORLADEYO. Oral administration is a meaningful differentiator in markets where injectable alternatives exist. The UQS Moat pillar currently rates this advantage as Neutral, reflecting a competitive position that is real but still maturing.
What sector does BCRX belong to?
BioCryst Pharmaceuticals operates in the Healthcare sector, specifically within biotechnology. The company focuses on rare diseases and antiviral medicine, areas that tend to attract specialized investors comfortable with clinical-stage risk and long development timelines.
Is BCRX a growth stock or value stock?
Based on UQS pillar labels, BCRX sits in an intermediate position. The Growth pillar is Neutral, meaning it does not clearly qualify as a high-growth name, while the Valuation pillar is rated Good — suggesting it is not priced at a premium typical of pure growth stocks. It may appeal to investors seeking a balance of quality and reasonable pricing.
Unlock Full BCRX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access complete financial metrics and trend data
- ✓Compare BCRX against sector peers side by side
- ✓Track pipeline risk factors within the Risk pillar detail
- ✓Get the full valuation breakdown behind the Good rating
- ✓Explore screener presets filtering for small-cap biotech quality
Pro Analysis
BCRX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 53.6 | 50.0 | 41.0 | 50.7 | 72.1 | 66.1 | 0.0 |
| May 22, 2026 | 53.6 | 50.0 | 41.0 | 50.7 | 72.1 | 65.9 | +0.1 |
| May 21, 2026 | 53.5 | 50.0 | 41.0 | 50.7 | 72.1 | 65.0 | +0.1 |
| May 20, 2026 | 53.4 | 50.0 | 41.0 | 50.7 | 72.1 | 64.9 | 0.0 |
| May 17, 2026 | 53.4 | 50.0 | 41.0 | 50.7 | 72.1 | 64.4 | -0.3 |
| May 16, 2026 | 53.7 | 50.0 | 41.0 | 50.7 | 72.1 | 66.4 | +0.2 |
| May 14, 2026 | 53.5 | 50.0 | 41.0 | 50.7 | 72.1 | 65.2 | +1.4 |
| May 13, 2026 | 52.1 | 50.0 | 41.0 | 50.7 | 61.1 | 66.9 | -0.1 |
| May 11, 2026 | 52.2 | 50.0 | 41.0 | 50.7 | 61.1 | 67.4 | -10.3 |
| May 7, 2026 | 62.5 | 83.3 | 41.0 | 51.0 | 60.3 | 80.9 | +0.2 |
BCRX — Pillar Breakdown
Quality
— 50.0/100 (25%)BioCryst Pharmaceuticals, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 50.7/100 (20%)BioCryst Pharmaceuticals, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 72.1/100 (15%)BioCryst Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 66.1/100 (15%)BioCryst Pharmaceuticals, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
Moat
— 41/100 (25%)BioCryst Pharmaceuticals, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BCRX.
Score Composition
Financial Data
More Stock Analysis
How is the BCRX UQS Score Calculated?
The UQS (Unified Quality Score) for BioCryst Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses BioCryst Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether BioCryst Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.